ArticleIranian journal of pharmaceutical research : IJPR2012
Situation analysis of R & d activities: an empirical study in Iranian pharmaceutical companies.
Article in Iranian journal of pharmaceutical research : IJPR, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 25 citations in OpenAlex.
- Key Factors to Improve Pharmaceutical Industry's R&D Productivity: A Case Study of Iranian Pharmaceutical Holding.Medical journal of the Islamic Republic of Iran · 2022Article
- Economic and non-economic determinants of Iranian pharmaceutical companies' financial performance: an empirical study.BMC health services research · 2019Article
- The Structure of the World Pharmaceutical Market: Prioritizing Iran's Target Export Markets.Iranian journal of pharmaceutical research : IJPR · 2019Article
- Policy Analysis Of Iranian Pharmaceutical Sector; A Qualitative Study.Risk management and healthcare policy · 2019Article
- Human Resource Management Challenges to Develop Pharmaceutical Industry: Evidence from Developing Countries.Iranian journal of pharmaceutical research : IJPR · 2018Article
- Information flow in the pharmaceutical supply chain.Iranian journal of pharmaceutical research : IJPR · 2015Article
- Identifying and prioritizing industry-level competitiveness factors: evidence from pharmaceutical market.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2014Article
- Development of an integrated performance measurement (PM) model for pharmaceutical industry.Iranian journal of pharmaceutical research : IJPR · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As global competition intensifies, research and development (R & D) organizations need to enhance their strategic management in order to become goal-directed communities for innovation and allocate their resources consistent with their overall R & D strategy. The world pharmaceutical market has undergone fast, unprecedented, tremendous and complex changes in the last several years. The pharmaceutical industry is today still one of the most inventive, innovative and lucrative of the so-called "high-tech" industries. This industry serves a dual role in modern society. On one hand, it is a growing industry, and its output makes a direct contribution to gross domestic product (GDP). On the other side, drugs, this industry's major output, are an input in the production of good health. The purpose of this study is to evaluate R & D activities of pharmaceutical companies, and also to highlight critical factors which have influential effect on results of these activities. To run this study a valid questionnaire based on literature review and experts' opinion was designed and delivered to 11 pharmaceutical companies. Empirical data show there is not acceptable situations considering of the factors that should be taken in to account by managers including; management commitment, human resource management, information technology and financial management. Furthermore, we concluded some interesting results related to different aspects of R & D management. In conclusion, managers must be aware about their performance in R & D activities, accordingly they will able to take a comprehensive policy in both national and within the company.
Identifiers
24250532PMC3813171W1783699888What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.